Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DiObex Inc.

This article was originally published in Start Up

Executive Summary

DiObex Inc. is named for the diseases its founders hope to treat-diabetes, obesity, and syndrome X, a poorly understood precursor to Type II diabetes. The company has in-licensed and is developing two products: DIO-901, a long-acting glucagon to prevent insulin-induced hypoglycemia in Type I diabetics, and DIO-902, a cortisol synthesis inhibitor to treat metabolic disorders such as Type II diabetes and syndrome X.

You may also be interested in...



Enject's GlucaPen: Mightier than the Hypo-kit?

Decades after recombinant insulin first hit the market insulin is still big business. But in the race to lock up that market, the big players haven't done much to address a key problem with treating high blood sugar with insulin--a better way to inject the hormone glucagon when blood sugar levels drop way too low, or hypoglycemia. Enter Enject. The start-up has amassed exclusive worldwide commercial licenses to several pieces of technology that have enabled it to develop an auto-injector pen similar to the EpiPen, which is used to administer epinephrine in the event of severe allergic reactions. Enject hopes it can parlay its nifty device into a lucrative business development deal with one of the big insulin drug or device players.

Enject's GlucaPen: Mightier than the Hypo-kit?

Decades after recombinant insulin first hit the market insulin is still big business. But in the race to lock up that market, the big players haven't done much to address a key problem with treating high blood sugar with insulin--a better way to inject the hormone glucagon when blood sugar levels drop way too low, or hypoglycemia. Enter Enject. The start-up has amassed exclusive worldwide commercial licenses to several pieces of technology that have enabled it to develop an auto-injector pen similar to the EpiPen, which is used to administer epinephrine in the event of severe allergic reactions. Enject hopes it can parlay its nifty device into a lucrative business development deal with one of the big insulin drug or device players.

Enject's GlucaPen: Mightier than the Hypo-kit?

Decades after recombinant insulin first hit the market insulin is still big business. But in the race to lock up that market, the big players haven't done much to address a key problem with treating high blood sugar with insulin--a better way to inject the hormone glucagon when blood sugar levels drop way too low, or hypoglycemia. Enter Enject. The start-up has amassed exclusive worldwide commercial licenses to several pieces of technology that have enabled it to develop an auto-injector pen similar to the EpiPen, which is used to administer epinephrine in the event of severe allergic reactions. Enject hopes it can parlay its nifty device into a lucrative business development deal with one of the big insulin drug or device players.

Related Content

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091157

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel